Matthew Foster
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Year:
2026
Year:
2025
Year:
2025
The proteomic analysis of blood is routine for disease phenotyping and biomarker development. Blood is commonly separated into soluble and cellular fractions. However, this can introduce pre‐analytical variability, and analysis of a single component (which is common) may ignore important pathophysiology. We have recently developed methods for the facile processing of dried blood for mass spectrometry‐based quantification of the proteome, N‐glycoproteome, and phosphoproteome. Here, we applied this approach to 38 patients in Tanzania who presented to the hospital with sepsis. Blood was collected on Mitra devices at presentation and 1, 3, and 28–42 days post‐enrollment. Processing of 96 total samples was performed in plate‐based formats and completed within 2 days. Approximately 2000 protein groups and 8000 post‐translational modifications were quantified in 3 LC‐MS/MS runs at ∼1.5 h per sample. Analysis of differential abundance revealed blood proteome signatures of acute phase response and neutrophilic inflammation that partially resolved at the 28–42 day timepoint. Numerous analytes correlated with clinical laboratory values for c‐reactive protein and white blood cell counts, as well as the Universal Vital Assessment illness severity score. These datasets serve as proof‐of‐concept for large‐scale MS‐based (sub)phenotyping of disease using dried blood and are available via the ProteomeXchange consortium (PXD060377). Summary For the first time, we report the integrated quantitative analysis of proteins, N‐glycopeptides, and phosphopeptides from dried blood specimens in a disease context. Sample collection on Mitra devices is easily incorporated into existing biobanking protocols and provides a convenient solution for sample storage and preparation for downstream mass spectrometry analysis. Signatures of sepsis are reflected in each of the analyzed proteomes and decline between presentation to the hospital and 1 month post. In addition to well‐described markers, these analyses identify mediators of inflammation and innate immune signaling that would be missed in the more common analysis of cell‐free plasma.
Year:
2025
Introduction Myocardial accumulation of the protein transthyretin (TTR) can result in amyloid TTR cardiomyopathy (ATTR-CM), a form of restrictive heart disease with limited therapies and still generally poor clinical outcomes. The mechanisms by which TTR fibril accumulation elicits cardiac toxicity at the protein level remain largely unknown. Accordingly, we performed untargeted proteomics of ventricular myocardium from patients with ATTR-CM versus controls. Methods Myocardial tissue from non-failing (NF) controls (n=7) and ATTR-CM (n=4) were assayed by mass spectrometry. HFrEF, HCM, and HFpEF proteomics were acquired from published databases. Results A total of 539/7093 (7.6% of total) proteins were found to be differentially expressed in ATTR-CM, 227/359 (42%) upregulated and 312/539 (58%) downregulated. Gene ontology pathway analysis found that downregulated proteins were enriched for oxidative phosphorylation and mitochondrial protein translation pathways, while upregulated proteins were enriched for enhanced endocytosis and intracellular vesicle mediated transport. The latter is not observed in other forms of heart failure. We further identify a profound downregulation of sarcomere protein content, which is also not seen in other cardiomyopathies. Conclusion The ATTR-CM myocardial proteome identifies endocytosis and intracellular transport as uniquely upregulated processes, whereas sarcomere protein content is uniquely downregulated. Both maybe potential therapeutic targets.
Year:
2025
The proteomic analysis of blood is routine for disease phenotyping and biomarker development. Whole blood is commonly separated into soluble and cellular fractions. However, this can introduce pre-analytical variability; and analysis of a single component (which is common) may ignore important pathophysiology. We have recently developed methods for the facile processing of dried blood for mass spectrometry-based quantification of the proteome, N-glycoproteome and phosphoproteome. Here, we applied this approach to 38 patients in Tanzania who presented to the hospital with sepsis. Blood was collected on Mitra devices at presentation and 1, 3 and 28-42 days post-enrollment. Processing of 96 total samples was performed in plate-based formats and completed within two days. Approximately 2,000 protein groups and 8,000 post-translational modifications were quantified in 3 LC-MS/MS runs at ∼1.5 hours per sample. Analysis of differential abundance revealed blood proteome signatures of acute phase response and neutrophilic inflammation that partially resolved at the 28-42 day timepoint. Numerous analytes correlated with clinical laboratory values for c-reactive protein and white blood cell counts, as well as the Universal Vital Assessment illness severity score. These datasets serve as proof-of-concept for large scale MS-based (sub)phenotyping of disease using dried blood and are available via the ProteomeXchange consortium (PXD060377).
Year:
2025
Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically approved PCSK9 inhibitor, which restores MHC-I expression in pre-clinical cancer models. However, monoclonal antibodies (mAbs) have limited blood brain/tumor barrier penetrance (BBB/BTB). The aim of this window-of-opportunity trial was to evaluate evolocumab’s BBB/BTB penetrance and biological effect in glioma (PesKE; NCT04937413). Patients with newly diagnosed/recurrent glioma undergoing a clinically indicated biopsy or resection were enrolled (n=32, M: 16, F: 16; control average age: 51.85, evolocumab: 53). Intervention participants (n=6) received subcutaneous evolocumab 4-14 days pre-procedure. 4/6 intervention participants provided research tissue. No significant adverse events were observed. Evolocumab was detected in all analyzed intervention tissue, with an average tumor:blood ratio of 0.0222 (SD±0.0190), akin to other mAbs. Evolocumab quantitation was 4.44x greater in contrast-enhancing (mean 0.0068 fmol/mcg (SD±0.001)) vs non-contrast enhancing cases (mean 0.0015 fmol/mcg (SD±0.0004)). Proteomic analysis found positive trends between evolocumab and MHC-I subtypes (HLA-A-C, E-G), with a significant positive correlation with HLA-H (R2=0.9584, p=0.021*). Tumor tissue with higher evolocumab titers demonstrated increased surface MHC-I and CD8+ T cell infiltration. Increased CD8+ TNF, FASLG and GZMA transcription was observed in high titer tissue compared to low titer tissue/untreated controls. Pre-resection evolocumab is well tolerated but exhibits BBB/BTB penetrance akin to other mAbs. Increased tumoral evolocumab/PCSK9i may enhance tumoral MHC-I/effector CD8+ infiltration. Future work will explore combining evolocumab with BBB/BTB opening therapies like low-intensity focused ultrasound. One Sentence Summary: We conducted a tissue-based study in glioma patients to evaluate if peripheral evolocumab enters tumors, enhances surface MHC-I, and boosts effector CD8+ T cell infiltration.
Year:
2025
It is increasingly recognized that the ‘omic analysis of whole blood has applications for precision medicine and disease phenotyping. Despite this realization, whole blood is generally viewed as a challenging analytical matrix in comparison to plasma or serum. Moreover, proteomic analyses of whole blood proteomics have almost exclusively focused on (non)targeted analyses of protein abundances and much less on post-translational modifications (PTMs). Here, we developed a streamlined workflow for processing twenty microliters of venous blood collected by volumetric absorptive microsampling that incorporates serial trypsinization, N-glycopeptide and phosphopeptide enrichment and avoids laborious sample dry-down or cleanup steps. Up to 10,000 analytes (reported as protein groups, glycopeptidoforms and phosphosites) were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in approximately 2 h of MS acquisition time. Using these methods, we explored the stability of “dried” and “wet” blood proteomes, as well as effects of ex vivo inflammatory stimulus or phosphatase inhibition. Multi-omics factor analysis enabled facile identification of analytes that contributed to inter-individual variability of the blood proteomes, including N-glycopeptides that distinguish immunoglobulin heavy constant alpha 2 allotypes. Collectively, our results help to establish feasibility and best practices for the integrated MS-based quantification of proteins and PTMs from dried blood.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Year:
2021
Year:
2020
Collaborators (19)
Micah McClain
Associate Professor of Medicine
Duke University Medical Center
Mustafa Khasraw
Professor
Duke University
Anoop Patel
Associate Professor
Duke University
Peter E. Fecci
Chair and Professor
Duke University Medical Center
Sandhya Manohar
Junior Group Leader
University of Zurich
Mark Ranek
Assistant Professor
Johns Hopkins University
Purushothama Rao Tata
Duke University
Chuan-Yuan Li
Professor and Vice Chair for Research
Duke University School of Medicine
John A. Crump
Professor of Medicine, Pathology, and Global Health
University of Otago
Daniel Rocke
Assistant Professor
Duke University
Deng Madut
Assistant Professor
Duke University
David Kass
Professor, Researcher, Lab Director
Johns Hopkins University
Walter T. Lee
Duke University
Miles Berger
Neuroanesthesiology Section Chief and Professor, University Medical Line
Stanford University
Michael Devinney
Assistant Professor
Duke University
Annick Desjardins
Professor of Neurosurgery and Neurology
Duke University
Simon G. Gregory
Professor
Duke University
Tim J. McMahon
Duke University Medical Center
ROGER MCLENDON
Professor
Duke University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.